• SPX
  • $5,731.86
  • 0.05 %
  • $3.06
  • DJI
  • $41,943.81
  • -0.26 %
  • -$108.39
  • N225
  • $38,053.67
  • -2.63 %
  • -$1,027.58
  • FTSE
  • $8,218.41
  • 0.5 %
  • $41.26
  • IXIC
  • $18,224.53
  • -0.08 %
  • -$15.38
Citius Pharmaceuticals Inc (CTXRW) Stock Price, News & Analysis

Citius Pharmaceuticals Inc (CTXRW) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$0.02
Day's range
$0.15
  • Sector: N/A
  • Industry: N/A
50-day range
$0.0122
Day's range
$0.29
  • Country: US
  • ISIN:
52 wk range
$0.02
Day's range
$0.15
  • CEO: None
  • Website: N/A
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score N/A
  • Piotroski Score N/A
  • Grade N/A
  • Symbol (CTXRW)
  • Company Citius Pharmaceuticals Inc
  • Price $0.14
  • Changes Percentage (-3.93%)
  • Change -$0.01
  • Day Low $0.02
  • Day High $0.15
  • Year High $0.15

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) N/A
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.00
  • Trailing P/E Ratio 0
  • Forward P/E Ratio 0
  • P/E Growth 0
  • Net Income $-23,054,434

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.